CA2046621A1 - Utilisation des micro-ondes a des fins immunologiques - Google Patents

Utilisation des micro-ondes a des fins immunologiques

Info

Publication number: CA2046621A1
Authority: CA; Canada
Prior art keywords: radionuclide; therapeutic radionuclide; therapeutic; stabilizing agent; preparation
Prior art date: 1989-02-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA 2046621

Other languages

English (en)

Inventor

Peter G. Bundeson

Dennis B. Rylatt

Carmel J. Hillyard

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Agen Ltd

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-02-03

Filing date

1990-02-05

Publication date

1990-08-04

1990-02-05 Application filed by Individual filed Critical Individual

1990-08-04 Publication of CA2046621A1 publication Critical patent/CA2046621A1/fr

Status Abandoned legal-status Critical Current

Links

230000001900 immune effect Effects 0.000 title 1
230000001225 therapeutic effect Effects 0.000 claims description 94
239000000203 mixture Substances 0.000 claims description 85
238000002360 preparation method Methods 0.000 claims description 83
239000003381 stabilizer Substances 0.000 claims description 56
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 55
230000008685 targeting Effects 0.000 claims description 55
239000003795 chemical substances by application Substances 0.000 claims description 37
238000000034 method Methods 0.000 claims description 34
WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 claims description 34
229910052702 rhenium Inorganic materials 0.000 claims description 33
235000010323 ascorbic acid Nutrition 0.000 claims description 27
229960005070 ascorbic acid Drugs 0.000 claims description 27
239000011668 ascorbic acid Substances 0.000 claims description 27
102000008100 Human Serum Albumin Human genes 0.000 claims description 24
108091006905 Human Serum Albumin Proteins 0.000 claims description 24
230000000694 effects Effects 0.000 claims description 23
238000000746 purification Methods 0.000 claims description 18
239000003963 antioxidant agent Substances 0.000 claims description 13
235000006708 antioxidants Nutrition 0.000 claims description 13
102000009027 Albumins Human genes 0.000 claims description 11
108010088751 Albumins Proteins 0.000 claims description 11
239000011541 reaction mixture Substances 0.000 claims description 11
230000003750 conditioning effect Effects 0.000 claims description 8
102000004506 Blood Proteins Human genes 0.000 claims description 6
108010017384 Blood Proteins Proteins 0.000 claims description 6
238000000338 in vitro Methods 0.000 claims description 6
238000001727 in vivo Methods 0.000 claims description 6
230000003078 antioxidant effect Effects 0.000 claims description 5
239000000470 constituent Substances 0.000 claims description 5
238000003860 storage Methods 0.000 claims description 5
239000003085 diluting agent Substances 0.000 claims 1
201000010099 disease Diseases 0.000 claims 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
230000001613 neoplastic effect Effects 0.000 claims 1
238000003745 diagnosis Methods 0.000 abstract description 3
239000000032 diagnostic agent Substances 0.000 abstract description 3
229940039227 diagnostic agent Drugs 0.000 abstract description 3
238000005516 engineering process Methods 0.000 abstract description 2
239000003814 drug Substances 0.000 abstract 2
239000000463 material Substances 0.000 abstract 2
229940124597 therapeutic agent Drugs 0.000 abstract 2
208000030507 AIDS Diseases 0.000 abstract 1
230000000890 antigenic effect Effects 0.000 abstract 1
210000000987 immune system Anatomy 0.000 abstract 1
230000021615 conjugation Effects 0.000 description 25
150000001875 compounds Chemical class 0.000 description 23
239000002738 chelating agent Substances 0.000 description 22
-1 l86Re and l88Re Chemical compound 0.000 description 22
229940051022 radioimmunoconjugate Drugs 0.000 description 20
WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 18
230000006641 stabilisation Effects 0.000 description 18
238000011105 stabilization Methods 0.000 description 18
238000006243 chemical reaction Methods 0.000 description 16
150000002148 esters Chemical class 0.000 description 16
235000018102 proteins Nutrition 0.000 description 15
102000004169 proteins and genes Human genes 0.000 description 15
108090000623 proteins and genes Proteins 0.000 description 15
239000000243 solution Substances 0.000 description 14
239000013522 chelant Substances 0.000 description 13
238000000354 decomposition reaction Methods 0.000 description 13
229910052751 metal Inorganic materials 0.000 description 13
239000002184 metal Substances 0.000 description 13
125000000524 functional group Chemical group 0.000 description 12
125000000217 alkyl group Chemical group 0.000 description 11
125000001424 substituent group Chemical group 0.000 description 11
QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 10
OFQCQIGMURIECL-UHFFFAOYSA-N 2-[2-(diethylamino)ethyl]-2',6'-dimethylspiro[isoquinoline-4,4'-oxane]-1,3-dione;phosphoric acid Chemical compound OP(O)(O)=O.O=C1N(CCN(CC)CC)C(=O)C2=CC=CC=C2C21CC(C)OC(C)C2 OFQCQIGMURIECL-UHFFFAOYSA-N 0.000 description 9
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
229960005219 gentisic acid Drugs 0.000 description 9
230000007774 longterm Effects 0.000 description 9
239000012217 radiopharmaceutical Substances 0.000 description 8
229940121896 radiopharmaceutical Drugs 0.000 description 8
230000002799 radiopharmaceutical effect Effects 0.000 description 8
230000000087 stabilizing effect Effects 0.000 description 8
GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 8
125000003118 aryl group Chemical group 0.000 description 7
229940127121 immunoconjugate Drugs 0.000 description 7
230000002285 radioactive effect Effects 0.000 description 7
238000000163 radioactive labelling Methods 0.000 description 7
150000003384 small molecules Chemical class 0.000 description 7
229910052713 technetium Inorganic materials 0.000 description 7
210000001519 tissue Anatomy 0.000 description 7
239000002253 acid Substances 0.000 description 6
239000007864 aqueous solution Substances 0.000 description 6
210000004027 cell Anatomy 0.000 description 6
230000003647 oxidation Effects 0.000 description 6
238000007254 oxidation reaction Methods 0.000 description 6
239000000047 product Substances 0.000 description 6
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
125000004432 carbon atom Chemical group C* 0.000 description 5
238000010828 elution Methods 0.000 description 5
150000002500 ions Chemical class 0.000 description 5
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
150000001412 amines Chemical class 0.000 description 4
150000001720 carbohydrates Chemical group 0.000 description 4
239000012634 fragment Substances 0.000 description 4
239000003446 ligand Substances 0.000 description 4
230000005855 radiation Effects 0.000 description 4
238000003608 radiolysis reaction Methods 0.000 description 4
239000000126 substance Substances 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
102000003886 Glycoproteins Human genes 0.000 description 3
108090000288 Glycoproteins Chemical group 0.000 description 3
PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
238000013459 approach Methods 0.000 description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
150000001732 carboxylic acid derivatives Chemical group 0.000 description 3
238000001212 derivatisation Methods 0.000 description 3
229910052736 halogen Inorganic materials 0.000 description 3
125000001072 heteroaryl group Chemical group 0.000 description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
239000001301 oxygen Substances 0.000 description 3
150000003281 rhenium Chemical class 0.000 description 3
125000006850 spacer group Chemical group 0.000 description 3
241000894007 species Species 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
238000012360 testing method Methods 0.000 description 3
TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 2
CRTGSPPMTACQBL-UHFFFAOYSA-N 2,3-dihydroxycyclopent-2-en-1-one Chemical compound OC1=C(O)C(=O)CC1 CRTGSPPMTACQBL-UHFFFAOYSA-N 0.000 description 2
DVALMHFCJYLXPH-AKGSDVBQSA-N 2-[(4-(131I)iodanylbenzoyl)amino]acetic acid Chemical compound OC(=O)CNC(=O)c1ccc([131I])cc1 DVALMHFCJYLXPH-AKGSDVBQSA-N 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 2
CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
229910021626 Tin(II) chloride Inorganic materials 0.000 description 2
125000003172 aldehyde group Chemical group 0.000 description 2
150000001299 aldehydes Chemical class 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
150000008064 anhydrides Chemical class 0.000 description 2
125000004429 atom Chemical group 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
239000003638 chemical reducing agent Substances 0.000 description 2
238000005695 dehalogenation reaction Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
238000002059 diagnostic imaging Methods 0.000 description 2
XQRLCLUYWUNEEH-UHFFFAOYSA-L diphosphonate(2-) Chemical compound [O-]P(=O)OP([O-])=O XQRLCLUYWUNEEH-UHFFFAOYSA-L 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
125000004404 heteroalkyl group Chemical group 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
239000012216 imaging agent Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
125000006303 iodophenyl group Chemical group 0.000 description 2
238000004255 ion exchange chromatography Methods 0.000 description 2
150000002540 isothiocyanates Chemical class 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
238000005259 measurement Methods 0.000 description 2
239000002609 medium Substances 0.000 description 2
230000001394 metastastic effect Effects 0.000 description 2
206010061289 metastatic neoplasm Diseases 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
238000009206 nuclear medicine Methods 0.000 description 2
239000002243 precursor Substances 0.000 description 2
239000012857 radioactive material Substances 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000010405 reoxidation reaction Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000001119 stannous chloride Substances 0.000 description 2
235000011150 stannous chloride Nutrition 0.000 description 2
239000011593 sulfur Substances 0.000 description 2
229910052717 sulfur Inorganic materials 0.000 description 2
150000003495 technetium Chemical class 0.000 description 2
150000003573 thiols Chemical class 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
238000012546 transfer Methods 0.000 description 2
ZKWQSBFSGZJNFP-UHFFFAOYSA-N 1,2-bis(dimethylphosphino)ethane Chemical group CP(C)CCP(C)C ZKWQSBFSGZJNFP-UHFFFAOYSA-N 0.000 description 1
150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
CFMZSMGAMPBRBE-UHFFFAOYSA-N 2-hydroxyisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(O)C(=O)C2=C1 CFMZSMGAMPBRBE-UHFFFAOYSA-N 0.000 description 1
JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
206010005949 Bone cancer Diseases 0.000 description 1
208000018084 Bone neoplasm Diseases 0.000 description 1
ZHMNTUACCGWZLK-UHFFFAOYSA-B C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-].[Re+4].C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-].C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-].C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-].[Re+4].[Re+4] Chemical compound C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-].[Re+4].C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-].C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-].C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-].[Re+4].[Re+4] ZHMNTUACCGWZLK-UHFFFAOYSA-B 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
102000003951 Erythropoietin Human genes 0.000 description 1
108090000394 Erythropoietin Proteins 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
239000004606 Fillers/Extenders Substances 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
102000011845 Iodide peroxidase Human genes 0.000 description 1
108010036012 Iodide peroxidase Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
102000004856 Lectins Human genes 0.000 description 1
108090001090 Lectins Proteins 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
229910019599 ReO2 Inorganic materials 0.000 description 1
229910002785 ReO3 Inorganic materials 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
208000033781 Thyroid carcinoma Diseases 0.000 description 1
208000024770 Thyroid neoplasm Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
208000017733 acquired polycythemia vera Diseases 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
125000002877 alkyl aryl group Chemical group 0.000 description 1
150000001350 alkyl halides Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
238000005349 anion exchange Methods 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000004791 biological behavior Effects 0.000 description 1
230000008512 biological response Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
239000011449 brick Substances 0.000 description 1
239000008366 buffered solution Substances 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
150000001728 carbonyl compounds Chemical class 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000011097 chromatography purification Methods 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
229940047120 colony stimulating factors Drugs 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
239000000039 congener Substances 0.000 description 1
230000001268 conjugating effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000001934 delay Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000007324 demetalation reaction Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
125000004663 dialkyl amino group Chemical group 0.000 description 1
125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 1
JXSJBGJIGXNWCI-UHFFFAOYSA-N diethyl 2-[(dimethoxyphosphorothioyl)thio]succinate Chemical compound CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC JXSJBGJIGXNWCI-UHFFFAOYSA-N 0.000 description 1
KZNICNPSHKQLFF-UHFFFAOYSA-N dihydromaleimide Natural products O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000007323 disproportionation reaction Methods 0.000 description 1
230000005264 electron capture Effects 0.000 description 1
238000007336 electrophilic substitution reaction Methods 0.000 description 1
229940105423 erythropoietin Drugs 0.000 description 1
229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000004133 fatty acid degradation Effects 0.000 description 1
239000003527 fibrinolytic agent Substances 0.000 description 1
230000003480 fibrinolytic effect Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 1
229960003692 gamma aminobutyric acid Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
150000004676 glycans Chemical group 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
150000004820 halides Chemical group 0.000 description 1
230000036541 health Effects 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
150000002429 hydrazines Chemical class 0.000 description 1
JUINSXZKUKVTMD-UHFFFAOYSA-N hydrogen azide Chemical class N=[N+]=[N-] JUINSXZKUKVTMD-UHFFFAOYSA-N 0.000 description 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
150000002463 imidates Chemical class 0.000 description 1
230000028993 immune response Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
208000014674 injury Diseases 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
AMZMQXJQIYKBJU-UHFFFAOYSA-N iodo benzoate Chemical compound IOC(=O)C1=CC=CC=C1 AMZMQXJQIYKBJU-UHFFFAOYSA-N 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229910052747 lanthanoid Inorganic materials 0.000 description 1
150000002602 lanthanoids Chemical class 0.000 description 1
239000005355 lead glass Substances 0.000 description 1
239000002523 lectin Substances 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
108700003824 lysine(6)-glutaryl-2-anthraquinone LHRH Proteins 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
BRMYZIKAHFEUFJ-UHFFFAOYSA-L mercury diacetate Chemical compound CC(=O)O[Hg]OC(C)=O BRMYZIKAHFEUFJ-UHFFFAOYSA-L 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
208000037819 metastatic cancer Diseases 0.000 description 1
208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
239000003607 modifier Substances 0.000 description 1
229910052750 molybdenum Inorganic materials 0.000 description 1
239000011733 molybdenum Substances 0.000 description 1
125000002950 monocyclic group Chemical group 0.000 description 1
150000005480 nicotinamides Chemical class 0.000 description 1
150000002825 nitriles Chemical class 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
125000006501 nitrophenyl group Chemical group 0.000 description 1
IQZPDFORWZTSKT-UHFFFAOYSA-N nitrosulphonic acid Chemical compound OS(=O)(=O)[N+]([O-])=O IQZPDFORWZTSKT-UHFFFAOYSA-N 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
229940061319 ovide Drugs 0.000 description 1
238000006213 oxygenation reaction Methods 0.000 description 1
238000002638 palliative care Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
QPCDCPDFJACHGM-UHFFFAOYSA-K pentetate(3-) Chemical compound OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O QPCDCPDFJACHGM-UHFFFAOYSA-K 0.000 description 1
239000000813 peptide hormone Substances 0.000 description 1
KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
150000002978 peroxides Chemical class 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
208000037244 polycythemia vera Diseases 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000008569 process Effects 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
239000012264 purified product Substances 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
238000010791 quenching Methods 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000002468 redox effect Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
150000003282 rhenium compounds Chemical class 0.000 description 1
YSZJKUDBYALHQE-UHFFFAOYSA-N rhenium trioxide Chemical compound O=[Re](=O)=O YSZJKUDBYALHQE-UHFFFAOYSA-N 0.000 description 1
IOVGROKTTNBUGK-SJCJKPOMSA-N ritodrine Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 description 1
230000007017 scission Effects 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
125000000547 substituted alkyl group Chemical group 0.000 description 1
125000003107 substituted aryl group Chemical group 0.000 description 1
229960002317 succinimide Drugs 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
229930192474 thiophene Natural products 0.000 description 1
201000002510 thyroid cancer Diseases 0.000 description 1
208000013077 thyroid gland carcinoma Diseases 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000008733 trauma Effects 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
239000002699 waste material Substances 0.000 description 1

Landscapes

Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

CA 2046621 1989-02-03 1990-02-05 Utilisation des micro-ondes a des fins immunologiques Abandoned CA2046621A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
AUPJ253489		1989-02-03
AUPJ2534		1989-02-03

Publications (1)

Publication Number	Publication Date
CA2046621A1 true CA2046621A1 (fr)	1990-08-04

Family

ID=3773683

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2046621 Abandoned CA2046621A1 (fr)	1989-02-03	1990-02-05	Utilisation des micro-ondes a des fins immunologiques

Country Status (1)

Country	Link
CA (1)	CA2046621A1 (fr)

1990
- 1990-02-05 CA CA 2046621 patent/CA2046621A1/fr not_active Abandoned

Publication	Publication Date	Title
US5679318A (en)	1997-10-21	Stable therapeutic radionuclide compositions and methods for preparation thereof
US5393512A (en)	1995-02-28	Stable therapeutic radionuclide compositions and methods for preparation thereof
JP3853354B2 (ja)	2006-12-06	放射性標識ペプチドおよびタンパク質の自己放射線分解を防止する安定剤
US5171563A (en)	1992-12-15	Cleavable linkers for the reduction of non-target organ retention of immunoconjugates
EP0237150B1 (fr)	1996-09-04	Couplage de radionuclide et d'anticorps
US5606028A (en)	1997-02-25	Anchimeric radiometal chelating compounds
EP0137457A2 (fr)	1985-04-17	Conjugués de métallothionéine et de molécules biologiquement actives chercheuses de cible, marqués par un traceur
JPH07504902A (ja)	1995-06-01	炎症造影用のテクネチウム−９９ｍ標識ペプチド
US5130118A (en)	1992-07-14	Methods and materials for the preparation of metal labelled antibody solutions
JPS58126817A (ja)	1983-07-28	放射性核種標識タンパク質、とくに抗体または抗体断片の製造法
US5746996A (en)	1998-05-05	Thiolation of peptides for radionuclide-based radiodetection and radiotherapy
KR930003312B1 (ko)	1993-04-26	메탈로티오네인과 생물학적 활성 분자의 추적-표지 결합체의 제조방법
KR860001565B1 (ko)	1986-10-08	방사성 진단제의 제조방법
EP0436664B1 (fr)	1994-11-09	Elements de liaison clivables pour la reduction de la retention d'immunoconjugues par des organes non cibles
US4758421A (en)	1988-07-19	Bleomycin conjugates and method
Bhalgat et al.	1997	Preparation and biodistribution of copper-67-labeled porphyrins and porphyrin-A6H immunoconjugates
CA2066779A1 (fr)	1991-03-23	Compositions a base de radionucleides therapeutiques stables, et leurs methodes de preparation
CA2066031C (fr)	2001-02-27	Methodes de reduction de la retention non recherchee d'immunoconjugues et metabolites obtenus
CA2046621A1 (fr)	1990-08-04	Utilisation des micro-ondes a des fins immunologiques
AU709219B2 (en)	1999-08-26	Thiolation of peptides for radionuclide-based radiodetection and radiotherapy
WO1993009816A1 (fr)	1993-05-27	Procede de diagnostic et de traitement du cancer
Ranadive et al.	1993	A new method of technetium-99m labeling of monoclonal antibodies through sugar residues. A study with TAG-72 specific CC-49 antibody
EP0793510A1 (fr)	1997-09-10	Procedes d'utilisation de nouveaux lyoprotecteurs et formulations instantanees en kit pour produits radiopharmaceutiques utilisant lesdits lyoprotecteurs
JP2548711B2 (ja)	1996-10-30	アミノ基と２官能性配位子を有する反応性高分子化合物とその利用
JPH0623114B2 (ja)	1994-03-30	放射性医薬品とその調製用高分子化合物

Legal Events

Date	Code	Title	Description
1996-08-05	FZDE	Dead